Tylenol is widely used right before or after a vaccine to prevent fever in babies. However, a new study shows that using Tylenol may reduce the effectiveness of the vaccine. With the widespread use of the seasonal and H1N1 Swine Flu vaccines, it may be a good idea not to use Tylenol after a child gets the vaccine.

A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

One of the major challenges in modern vaccinology is to engineer vectors that are highly infectious, yet don't cause illness. Trickier still is to ensure that such weapons against infectious disease can be safely disarmed, once their immunogenic work is done.

Most successful vaccines and drugs rely on protecting humans or animals by blocking certain bacteria from growing in their systems. But, a new theory actually hopes to take stopping infectious diseases such as West Nile virus and Malaria to the next level by disabling insects from transmitting these viruses.

In the first study of its kind, researchers at the Yerkes National Primate Research Center and Emory Vaccine Center, Emory University, have developed a multidisciplinary approach involving immunology, genomics and bioinformatics to predict the immunity of a vaccine without exposing individuals to infection.

To avoid producing vaccines that treat the wrong strains during flu season, the FDA should consider deferring some of its selections as well as other changes to the vaccine composition, according to a study by two decision analysts published in a journal of the Institute for Operations Research and the Management Sciences.

Researchers from Maryland and South Carolina have developed a novel four-component vaccine that protects monkeys against all four strains of dengue virus and may potentially offer protection to the millions of humans at risk worldwide. They report their findings in the July 2008 issue of the Journal of Virology.

Emergency room workers will be the first line of defense in the event of a disease pandemic and will be forced to deal with the chaos that inevitably comes with treating thousands of sick and dying.

La Jolla Institute for Allergy & Immunology (LIAI) scientists have discovered one for the textbooks. Their finding, reported Friday in the scientific journal Immunity, illuminates a new, previously unknown mechanism in how the body fights a virus.

One of the most pressing biomedical issues is the development of techniques that increase the efficiency of vaccines. In a paper published on April 24, 2008 in the journal Vaccine, a Massachusetts’s biotechnology company, Cure Lab, Inc. has proposed a new technology for anti-viral vaccination.

The vaccinia virus has a problem: it is a giant among viruses and needs a special strategy in order to infiltrate a cell and reproduce. Professor Ari Helenius and Postdoc Jason Mercer from ETH Zurich’s Institute for Biochemistry have now discovered what this strategy is.

New Analysis by Applied Data Research Examines Clinical Developments and Assesses Healthcare Impact